

**North America Travel Vaccines Market Report by Composition (Mono Vaccines, Combination Vaccines), Disease (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, and Others), and Country 2026-2034**

Market Report | 2026-02-01 | 140 pages | IMARC Group

**AVAILABLE LICENSES:**

- Electronic (PDF) Single User \$3999.00
- Five User Licence \$4999.00
- Enterprisewide License \$5999.00

**Report description:**

The North America travel vaccines market size reached USD 2.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.33% during 2026-2034.

Vaccines are defined as biological preparations that protect the human body against severe and potentially deadly diseases. They generally consist of an agent made from the surface protein, toxins, weakened or killed forms of the disease-causing microorganisms. Vaccination enables the body to produce antibodies, which provide a shield in case the person is exposed to the disease. For travel vaccines, also known as travel immunizations, travelers are vaccinated 4 to 6 weeks before the journey. These can be differentiated between recommended and required vaccines. Wherein, required vaccines are essential for the individual to get before entering a country. However, recommended vaccines are those which the traveler may need because of a potential infection threat in the country or a part of that country. Some of the most common vaccine-preventable, travel-related diseases include influenza, meningitis, rabies, tick-borne encephalitis, polio, diphtheria, tetanus, pertussis, etc.

North America travel vaccines market is currently being driven by several factors. One of the key factors driving the demand of travel vaccines is their ability to prevent the risk of disease epidemic. Moreover, vaccination provides immunity to individuals, travelling to places where there is a high risk of exposure or contracting a specific disease. As a result, governments in the region have mandated vaccination before visiting certain destinations with a high prevalence of infectious diseases. Other factors driving the demand of travel vaccines in the region include rising number of travelers, government initiatives, technological advancements such as combination vaccines and needle free techniques, etc.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the North America travel vaccines market report, along with forecasts at the regional and country levels from 2026-2034. Our report has categorized the market based on composition and disease.

### -□Key Regions Analysed

- o□United States
- o□Canada
- o□Mexico

### -□Analysis for Each Country

### -□Market by Composition

- o□Mono Vaccines
- o□Combination Vaccines

### -□Market by Disease

- o□Hepatitis A
- o□DPT
- o□Yellow Fever
- o□Typhoid
- o□Hepatitis B
- o□Measles and Mumps
- o□Rabies
- o□Meningococcal
- o□Varicella
- o□Japanese Encephalitis
- o□Others

### -□Value Chain Analysis

- Key Drivers and Challenges
- Porters Five Forces Analysis
- PESTEL Analysis
- Government Regulations
- Competitive Landscape
  - o□Competitive Structure
  - o□Key Player Profiles

## Key Questions Answered in This Report

- 1.What was the size of the North America travel vaccines market in 2025?
- 2.What is the expected growth rate of the North America travel vaccines market during 2026-2034?
- 3.What are the key factors driving the North America travel vaccines market?
- 4.What has been the impact of COVID-19 on the North America travel vaccines market?
- 5.What is the breakup of the North America travel vaccines market based on the composition?
- 6.What is the breakup of the North America travel vaccines market based on the disease?
- 7.What are the key regions in the North America travel vaccines market?

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## **Table of Contents:**

- 1 Preface
- 2 Scope and Methodology
  - 2.1 Objectives of the Study
  - 2.2 Stakeholders
  - 2.3 Data Sources
    - 2.3.1 Primary Sources
    - 2.3.2 Secondary Sources
  - 2.4 Market Estimation
    - 2.4.1 Bottom-Up Approach
    - 2.4.2 Top-Down Approach
  - 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
  - 4.1 Overview
  - 4.2 Key Industry Trends
- 5 Global Travel Vaccines Market
  - 5.1 Market Performance
  - 5.2 Market Breakup by Composition
  - 5.3 Market Breakup by Disease
  - 5.4 Market Breakup by Region
  - 5.5 Market Forecast
- 6 North America Travel Vaccines Market
  - 6.1 Market Performance
  - 6.2 Impact of COVID-19
  - 6.3 Market Forecast
- 7 North America Travel Vaccines Market: Breakup by Composition
  - 7.1 Mono Vaccines
  - 7.2 Combination Vaccines
- 8 North America Travel Vaccines Market: Breakup by Disease
  - 8.1 Hepatitis A
  - 8.2 DPT
  - 8.3 Yellow Fever
  - 8.4 Typhoid
  - 8.5 Hepatitis B
  - 8.6 Measles and Mumps
  - 8.7 Rabies
  - 8.8 Meningococcal
  - 8.9 Varicella
  - 8.10 Japanese Encephalitis
  - 8.11 Others
- 9 North America Travel Vaccines Market: Breakup by Country
  - 9.1 United States
    - 9.1.1 Historical Market Trends
    - 9.1.2 Market Breakup by Composition
    - 9.1.3 Market Breakup by Disease
    - 9.1.4 Market Forecast

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.2 Canada
  - 9.2.1 Historical Market Trends
  - 9.2.2 Market Breakup by Composition
  - 9.2.3 Market Breakup by Disease
  - 9.2.4 Market Forecast
- 9.3 Mexico
  - 9.3.1 Historical Market Trends
  - 9.3.2 Market Breakup by Composition
  - 9.3.3 Market Breakup by Disease
  - 9.3.4 Market Forecast
- 10 SWOT Analysis
  - 10.1 Overview
  - 10.2 Strengths
  - 10.3 Weaknesses
  - 10.4 Opportunities
  - 10.5 Threats
- 11 Value Chain Analysis
  - 11.1 Overview
  - 11.2 Exploratory Stage
  - 11.3 Preclinical and Clinical Development
  - 11.4 Regulatory Approval
  - 11.5 Manufacturing
  - 11.6 Marketing and Distribution
- 12 Porter's Five Forces Analysis
  - 12.1 Overview
  - 12.2 Bargaining Power of Buyers
  - 12.3 Bargaining Power of Suppliers
  - 12.4 Degree of Rivalry
  - 12.5 Threat of New Entrants
  - 12.6 Threat of Substitutes
- 13 Price Analysis
- 14 Competitive Landscape
  - 14.1 Market Structure
  - 14.2 Key Players
  - 14.3 Profiles of Key Players

?

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**North America Travel Vaccines Market Report by Composition (Mono Vaccines, Combination Vaccines), Disease (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, and Others), and Country 2026-2034**

Market Report | 2026-02-01 | 140 pages | IMARC Group

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

| Select license | License                      | Price     |
|----------------|------------------------------|-----------|
|                | Electronic (PDF) Single User | \$3999.00 |
|                | Five User Licence            | \$4999.00 |
|                | Enterprisewide License       | \$5999.00 |
|                |                              | VAT       |
|                |                              | Total     |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |                      |
|---------------|----------------------|-------------------------------|----------------------|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/> |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/> |
| Job title*    | <input type="text"/> |                               |                      |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address*      | <input type="text"/> | City*                         | <input type="text"/> |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/> |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-03-02

Signature

A large, empty rectangular box intended for a signature.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)